The British Journal of Psychiatry (2007) 191: 131-139. doi: 10.1192/bjp.bp.105.017020
© 2007 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by KEKS, N. A.
Right arrow Articles by KARCHER, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KEKS, N. A.
Right arrow Articles by KARCHER, K.

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder

Randomised, controlled, open-label study

NICHOLAS A. KEKS, MB, BS, MPM, PhD, FRANZCP

Mental Health Research Institute of Victoria and Monash University, Victoria, Australia

MICHAEL INGHAM, MSc, AKBAR KHAN, MD and KEITH KARCHER, MSc

Johnson & Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA

Correspondence: Professor Nicholas A. Keks, Delmont Hospital, 298 Warrigal Road, Glen Iris, VIC 3146, Australia. Email: Nicholas.keks{at}med.monash.edu.au

Declaration of interest N. K. has received support from or been a consultant for AstraZeneca, Bristol-Meyers Squibb, Janssen Pharmaceutica, Eli Lilly, Sanofi-Synthelabo, Pfizer and Wyeth. M.I., A.K. and K.K. are employees of Johnson & Johnson.

Background The efficacy and safety of long-acting injectable risperidone have not been compared with those of an oral atypical antipsychotic.

Aims To compare long-acting risperidone and oral olanzapine in 377 patients with DSM–IV schizophrenia or schizoaffective disorder.

Method Patients were randomised to receive long-acting risperidone (25 mg or 50 mg every 14 days) or olanzapine (5–20 mg/day).

Results In the 13-week phase, long-acting risperidone was at least as effective as (not inferior to) oral olanzapine. In the 12-month phase, significant improvements in the Positive and Negative Syndrome Scale (PANSS) total and factor scores from baseline to month 12 and end-point were seen in both groups of patients. Few patients discontinued treatment because of an adverse event.

Conclusions Both treatments were efficacious and well tolerated.


Related articles in BJP:

Highlights of this issue
KIMBERLIE DEAN
BJP 2007 191: A5. [Full Text]  



This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
D. Taylor
Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review
The British Journal of Psychiatry, November 1, 2009; 195(52): S13 - S19.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
P. M. Haddad, M. Taylor, and O. S. Niaz
First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies
The British Journal of Psychiatry, November 1, 2009; 195(52): S20 - S28.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
W. W. Fleischhacker
Second-generation antipsychotic long-acting injections: systematic review
The British Journal of Psychiatry, November 1, 2009; 195(52): S29 - S36.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
P. Tyrer
From the Editor's desk
The British Journal of Psychiatry, December 1, 2008; 193(6): 524 - 524.
[Full Text] [PDF]

eLetters:

Read all eLetters

Long acting injectable risperidone v olanzapine.
Satish K Karunakaran
BJP Online, 31 Oct 2007 [Full text]